← Browse by Condition
Medical Condition
myositis
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2
NCT06991114 Phase 2
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Enrollment
90 pts
Location
United States, Bulga...
Sponsor
Artiva Biotherapeutics, Inc.
NCT07374107
Recruiting
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Enrollment
700 pts
Location
United States
Sponsor
Myositis International Health ...
NCT06587724
Recruiting
Investigation of the Validity, Reliability, and Responsiveness of the BETY-BQ in Myositis
Enrollment
100 pts
Location
Turkey (Türkiye)
Sponsor
Hacettepe University